Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 7,623 matching trials from the live ClinicalTrials.gov search.
Filters: Jacksonville, Florida Clear all
Completed Phase 3 Interventional

Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease

NCT00031824
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
cyclosporine, hydroxychloroquine, prednisone, tacrolimus
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 29 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
89
States / cities
Tucson, Arizona • Little Rock, Arkansas • Downey, California + 67 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2014 · Synced Oct 31, 2026, 5:32 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Biospecimen Biorepository for the Study of ALS, ALS-FTD and Similar Neurodegenerative Disorders

NCT05116943
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2030
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 31, 2026, 5:32 PM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

NCT07023289
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Telisotuzumab Adizutecan, Standard of Care
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Huntsville, Alabama • Fullerton, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 31, 2026, 5:32 PM EDT
Recruiting Phase 2 Interventional

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

NCT07059091
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Allergies
Interventions
Omalizumab (Xolair®), Sodium Chloride (NaCl) 0.9 %
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 31, 2026, 5:32 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

NCT07088926
View directory record Official record
Conditions
Bronchiectasis With Pseudomonas Aeruginosa Colonization
Interventions
AZD0292, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
25
States / cities
Orange, California • San Francisco, California • Denver, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 31, 2026, 5:32 PM EDT
Terminated Phase 2 Interventional

Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis

NCT03245385
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Treatment with Halobetasol propionate 0.05% topical spray
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
12 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
13
States / cities
North Hollywood, California • Pasadena, California • Hialeah, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 31, 2026, 5:32 PM EDT
Recruiting Phase 3 Interventional

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

NCT05549297
View directory record Official record
Conditions
Advanced Melanoma
Interventions
Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice
Drug
Lead sponsor
Immunocore Ltd
Industry
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
25
States / cities
Phoenix, Arizona • Jacksonville, Florida • Orlando, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 31, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

NCT01716715
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Cabozantinib S-malate, Laboratory Biomarker Analysis, Paclitaxel
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
173
States / cities
Mobile, Alabama • Burbank, California • Concord, California + 119 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 31, 2026, 5:32 PM EDT
Completed Phase 4 Interventional Results available

A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder

NCT02288325
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Levomilnacipran ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
47
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Oct 31, 2026, 5:32 PM EDT
Completed Phase 3 Interventional Results available

Age-Related Eye Disease Study 2 (AREDS2)

NCT00345176
View directory record Official record
Conditions
Age-related Macular Degeneration, Cataract
Interventions
Lutein/zeaxanthin, DHA/EPA, Lutein/zeaxanthin and DHA/EPA
Dietary Supplement · Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years to 85 Years
Enrollment
4,203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
91
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 72 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 31, 2026, 5:32 PM EDT
Terminated Phase 3 Interventional Results available

AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)

NCT03028740
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
Placebo, Cenicriviroc
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,778 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
204
States / cities
Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 144 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 31, 2026, 5:32 PM EDT
Active, not recruiting Not applicable Interventional

Clinical Study of a Micro-Implantable Pulse Generator for the Treatment of Peripheral Neuropathic Pain (COMFORT 2)

NCT05870124
View directory record Official record
Conditions
Peripheral Neuralgia, Peripheral Neuropathy, Chronic Pain
Interventions
Nalu Neurostimulation System for PNS, Conventional Medical Management
Device · Other
Lead sponsor
Nalu Medical, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
17
States / cities
Tucson, Arizona • Burbank, California • Thousand Oaks, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 31, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study

NCT02300103
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
San Diego, California • San Marcos, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 31, 2026, 5:32 PM EDT
Completed Phase 3 Interventional

DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

NCT00330369
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan, Darusentan Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 31, 2026, 5:32 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Risk Minimization, Assessment and Outcomes in Patients With Chronic Pain Taking Avinza

NCT00640042
View directory record Official record
Conditions
Pain
Interventions
morphine sulfate extended release capsules
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
1,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
378
States / cities
Adamsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 314 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 31, 2026, 5:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects

NCT02372773
View directory record Official record
Conditions
Familial Frontotemporal Dementia
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
398 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
7
States / cities
San Francisco, California • Jacksonville, Florida • Charlestown, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 31, 2026, 5:32 PM EDT
Active, not recruiting Phase 3 Interventional

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

NCT04457596
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma, Anatomic Stage I Breast Cancer AJCC v8
Interventions
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2035
U.S. locations
1160
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 749 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 31, 2026, 5:32 PM EDT
Enrolling by invitation Phase 4 Interventional

Longitudinal Imaging Biomarkers of Disease Progression in DLB

NCT03582488
View directory record Official record
Conditions
Lewy Body Disease
Interventions
18F-Flortaucipir
Drug
Lead sponsor
Kejal Kantarci
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 31, 2026, 5:32 PM EDT
Completed Phase 4 Interventional

A Comparison of Tolerability and Efficacy of Different Doses of Duloxetine for the Treatment of Major Depressive Disorder

NCT00191061
View directory record Official record
Conditions
Depressive Disorder
Interventions
duloxetine hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
32
States / cities
Little Rock, Arkansas • Coral Springs, Florida • Jacksonville, Florida + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2007 · Synced Oct 31, 2026, 5:32 PM EDT
Completed Phase 2 Interventional Results available

Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer

NCT00284180
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer
Interventions
Vinflunine, Trastuzumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
10
States / cities
Anniston, Alabama • Fort Myers, Florida • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2013 · Synced Oct 31, 2026, 5:32 PM EDT
Recruiting Not applicable Interventional

Radial vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH)

NCT04077762
View directory record Official record
Conditions
Patient Satisfaction, Vascular Access Complication
Interventions
Radial Access, State-of-the-art femoral access with 18 gauge needle, State-of-the-art femoral access with 21 gauge needle
Procedure
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years and older
Enrollment
3,266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
6
States / cities
San Francisco, California • Jacksonville, Florida • Decatur, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 31, 2026, 5:32 PM EDT
Recruiting Phase 3 Interventional

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

NCT07322003
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Pridopidine, Placebo
Drug
Lead sponsor
Prilenia
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
18
States / cities
Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 31, 2026, 5:32 PM EDT
Recruiting Phase 2 Interventional

Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

NCT07708961
View directory record Official record
Conditions
Glioblastoma, IDH-Wildtype
Interventions
Archive Sample Retrieval, Biospecimen Collection, Chest Radiography, Echocardiography Test, EGFR/EGFRvIII Inhibitor WSD0922-FU, Magnetic Resonance Imaging, Temozolomide
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 31, 2026, 5:32 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Deliver-EE: Evaluating Effects of Meal Delivery

NCT05357261
View directory record Official record
Conditions
Healthy
Interventions
Wellness Check and Socialization, Prepared Meals
Behavioral · Other
Lead sponsor
Brown University
Other
Eligibility
66 Years and older
Enrollment
2,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
14
States / cities
San Diego, California • Clearwater, Florida • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 31, 2026, 5:32 PM EDT